Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Almirall Launches AK Global Day Campaign to Raise Awareness of Actinic Keratosis and Sun Exposure Risks

(IN BRIEF) Almirall’s new data highlights the alarming lack of awareness regarding actinic keratosis (AK), a common precancerous dermatological condition linked to sun exposure, with more than one-third of affected individuals unaware of its causes. The survey, conducted across Spain, … Read the full press release

Global Study Unveils Barriers to Mental Health Care Access

(IN BRIEF) A recent study commissioned by Boehringer Ingelheim, conducted across eight G20 countries, sheds light on the challenges obstructing access to mental health care worldwide. The analysis reveals pervasive stigma, a shortage of mental health professionals, and inconsistent service … Read the full press release

Roche Announces Retirement of Head of Pharma Partnering and Successor Appointment

(IN BRIEF) Roche (SIX: RO, ROG; OTCQX: RHHBY) reveals the retirement of James Sabry, the Head of Roche Pharma Partnering, after fourteen years of service. Effective 1 July 2024, Boris Zaïtra, currently Head of Group Business Development, will take on … Read the full press release

European Parliament Approves Landmark Pharmaceutical Legislation Reform, Calls for Further Enhancements

(IN BRIEF) The European Parliament has achieved a significant milestone by approving the first reading of extensive reforms to EU pharmaceutical legislation aimed at fostering innovation and ensuring equitable access to medicines. While commending the progress, the European Society of … Read the full press release

Boehringer Ingelheim and OSE Immunotherapeutics Forge New Paths in Disease Treatment Collaboration

(IN BRIEF) Boehringer Ingelheim and OSE Immunotherapeutics announce a significant expansion of their partnership, introducing two novel projects to develop pioneering treatments alongside their ongoing anti-SIRPα immuno-oncology initiatives. The expansion includes broadening therapeutic evaluations to encompass cardiovascular-renal-metabolic (CRM) diseases and … Read the full press release

Roche and Amgen Collaborate on Breakthrough Lp(a) Test for Cardiovascular Disease Risk

(IN BRIEF) Roche Diagnostics has announced that its Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Developed in collaboration with Amgen, this innovative test aims to identify individuals at risk … Read the full press release

AstraZeneca Unveils Groundbreaking Advances in Cancer Care at ASCO 2024

(IN BRIEF) AstraZeneca is set to revolutionize cancer care with a slew of groundbreaking data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. Over 100 abstracts will showcase 25 approved and potential new medicines, including two late-breaking … Read the full press release

Sartorius and NVIDIA Deepen Collaboration for AI-Powered Biopharma Innovation

(IN BRIEF) Sartorius, a prominent life science group, is expanding its collaboration with NVIDIA to advance the development of new therapies by integrating NVIDIA’s AI-powered computing platforms with Sartorius’ expertise in life sciences and bioprocessing. Since 2020, Sartorius has integrated … Read the full press release

WACKER Expands Biopharmaceutical Capabilities in the USA for Advanced Therapies

(IN BRIEF) WACKER is strategically enhancing its BIOSOLUTIONS life-science division by bolstering capacities in biopharmaceuticals for advanced therapies. Its subsidiary, Wacker Biotech US, based in San Diego, is expanding mRNA and protein production to meet the surging demand for contract … Read the full press release

AstraZeneca Completes Equity Investment in Cellectis for Cell and Gene Therapy Development

(IN BRIEF) AstraZeneca has finalized its equity investment with Cellectis, a clinical-stage biotechnology firm, following a successful research collaboration agreement announced in November 2023. This partnership aims to harness Cellectis’ gene editing technologies to design up to 10 novel cell … Read the full press release

Bayer and Evotec Forge Partnership for Next-Generation Cardiovascular Therapies

(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release

Positive Results from DESTINY-Breast06 Trial: Enhertu Shows Promise in HER2-Low and HER2-Ultralow Breast Cancer Patients

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant progress in treating HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. The high-level results from the DESTINY-Breast06 Phase … Read the full press release

AstraZeneca’s Truqap Receives EU Recommendation for ER-Positive Breast Cancer Treatment

(IN BRIEF) AstraZeneca’s Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for treating estrogen receptor-positive, HER2‑negative locally advanced or metastatic breast cancer with specific genetic alterations. The recommendation follows promising results from … Read the full press release

Evonik Expands RESOMER® Biomaterial Production with Advanced Micronization Technology

(IN BRIEF) Evonik has enhanced its capabilities for RESOMER® powder biomaterials at its Darmstadt site in Germany with the implementation of advanced solvent-free micronization technology. This innovation allows for the production of customized powders with varied particle sizes and material … Read the full press release

Evotec Biologics Unveils J.CHO™ High Expression System for Enhanced Antibody Production

(IN BRIEF) Evotec Biologics, the biologics arm of Evotec SE, has introduced its proprietary J.CHO™ High Expression System for antibody expression. J.CHO™ optimizes biotherapeutic production processes by providing higher productivity and quality for complex antibody formats. Engineered from Chinese hamster … Read the full press release

Sanofi’s Frexalimab Shows Promise in Phase 2 for Treating Multiple Sclerosis

(IN BRIEF) Sanofi’s experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis (MS). Presented at the American Academy of Neurology Annual Meeting, the data reveals sustained reduction in disease activity and favorable … Read the full press release

Evotec Appoints Aurélie Dalbiez as Chief People Officer to Drive Organizational Excellence

(IN BRIEF) Evotec SE announces the appointment of Aurélie Dalbiez as their new Chief People Officer (CPO), effective June 15, 2024. Joining the Management Board, Aurélie brings over 25 years of international Human Resources leadership experience, previously serving as the … Read the full press release

Long-Term Study Shows Sustained Efficacy of Kesimpta in Treating Relapsing Multiple Sclerosis

(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release

AstraZeneca’s IMPACT CKD Model Forecasts Alarming Rise in Chronic Kidney Disease by 2032

(IN BRIEF) AstraZeneca’s IMPACT CKD model predicts a significant increase in chronic kidney disease (CKD) across eight countries, with up to 16.5% of the population affected by 2032, including a substantial rise in advanced-stage cases. Presented at the 2024 ISN … Read the full press release

Advancing Healthcare: Bosch and Randox Labs Partner to Revolutionize Molecular Diagnostics

(IN BRIEF) Bosch and Randox Laboratories Ltd. have forged a strategic partnership aimed at transforming molecular diagnostics with a focus on the Vivalytic analysis platform. With an investment of 150 million euros in joint research, development, and distribution, the collaboration … Read the full press release